Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

Prostate

Volumn 39, Issue 2, 1999, Pages 123-129

  Miyake, Hideaki ^a,b   Hara, Isao ^a   Yamanaka, Kazuki ^a   Gohji, Kazuo ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Prognosis; Progression; Prostate cancer; Serum; UPA; UPA receptor

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033119221     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2     Document Type: Article

References (20)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;45:5-27.
2. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
3. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res 1990;50:6130-6138.
4. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-573.
5. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990;9:353-367.
6. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors. Correlation with aggressive phenotype. J Urol 1988;142:193-198.
7. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Akouchi A, Sinha AA, Wilson MJ. Heterogeneity in cellular levels of expression of plasminogen activators in human prostate cancer cell lines. Invasive cells contain and secrete more uPA. Prostate 1991;18:201-204.
8. Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L, Bologna M. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res 1995;7:131-138.
9. Crowly CW, Cohen RL, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5025.
10. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L-G, Brodt P, Goltzman D, Rabbani SA. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994;54:2372-2377.
11. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96: 2593-2600.
12. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995;63:840-845.
13. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF III. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-211.
14. Rahr HB, Sørensen JV, Larsen JF, Svenden Jensen F, Bredahl C. Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Haemostasis 1995;25:248-256.
15. Sier CFM, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dana K, Brunner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-1849.
16. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G. UICC, TNM atlas, 3rd ed. Berlin: Springer-Verlag; 1992.
17. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Febiger; 1977. p 171-197.
18. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
19. Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994;54:1105-1108.
20. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological staging in men with localized prostate cancer. J Urol 1993;150:110-114.